With COVID’s toll on delayed and canceled elective surgeries affecting all participants in the market, the US Hemostats and Sealants market dropped -32.4% in Q220 according to SmartTRAK Financial Dashboard, a decrease that was presaged in Q120 earnings reports. Baxter* led the decline in Q220, down -42.1% YoY, with the Company’s sealants experiencing the worst YoY shrinkage. Cryolife* was close behind as its BioGlue* franchise saw cardiac surgeries postponed nationwide. In Q220, Ethicon* remained the market leader, followed by Baxter.
Among the many topics covered in the comprehensive Q220 US Hemostats and Sealants Market Recap* are:
Though all manufacturers declined substantially in Q220, several manufacturers, such as Becton Dickinson* and Ethicon*, said there may be light at the end of the tunnel as their June biosurgery sales showed smaller declines than had been expected ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.